Business Context and Reporting Period
Company: Utah Medical Products, Inc. (UTMD)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter and six months ended June 30, 2002
Business Overview: UTMD manufactures and markets specialty medical devices, primarily in obstetrics, gynecology/electrosurgery/urology, neonatal, and blood pressure monitoring. The company operates manufacturing facilities in the U.S. and Ireland.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended 6/30/02 | 6 Months Ended 6/30/02 | 6 Months Ended 6/30/01 |
|---|---|---|---|
| Net Sales | $6,800 | $13,505 | $13,361 |
| Gross Profit | $3,917 | $7,733 | $7,684 |
| Operating Income | $2,602 | $5,124 | $4,575 |
| Net Income | $1,785 | $3,497 | $2,872 |
| Diluted EPS | $0.33 | $0.65 | $0.56 |
| Cash from Operations (6mo) | $3,780 | ||
| Cash Balance (6/30/02) | $823 | ||
| Long-Term Debt | $0 |
Margins (6 Months 2002): Gross Profit Margin: 57.3%; Operating Profit Margin: 37.9%; Net Profit Margin: 25.9%.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 1% year-over-year for the six months ended June 30, 2002 ($13,505 vs. $13,361). International sales rose 1%, while domestic OEM sales declined 12%.
- Profitability Expansion: Net income increased 22% year-over-year ($3,497 vs. $2,872). Operating income rose 12% due to reduced operating expenses.
- Debt Elimination: The company fully repaid its $2.5 million note payable during the first half of 2002, reducing total liabilities from $5.365 million (Dec 31, 2001) to $2.345 million (June 30, 2002).
- Expense Reduction: Operating expenses as a percentage of sales dropped from 23.3% in 1H 2001 to 19.3% in 1H 2002. This was driven by the cessation of goodwill amortization (per SFAS No. 142) and reduced litigation accruals following a favorable patent verdict.
- Share Repurchases: The company repurchased 66,000 shares for $995,000 in the first half of 2002.
Guidance, Outlook, and Risks
Management Outlook: Management expects to achieve a Return on Shareholders' Equity (ROE) of approximately 30% for the full year 2002. The company plans to sustain profitability records, recover damages from the patent infringement lawsuit, and pursue strategic acquisitions. Future S&M expenses are expected to rise due to new marketing initiatives.
Liquidity: The company maintains a strong cash position ($823,000) and recently secured a new $15 million unsecured revolving line of credit with U.S. Bank National Association to fund potential acquisitions or share repurchases.
Risks and Contingencies:
- Market Risks: Competition, product obsolescence, and reliance on third-party distributors.
- Foreign Exchange: Operations in Ireland are subject to currency fluctuations between the Euro and U.S. Dollar.
- Legal: Ongoing risks related to product liability claims and intellectual property defense.
- Concentration: Significant reliance on group purchasing organizations for U.S. hospital access.
Investor Verification Checklist
- Debt Status: Confirm the elimination of the $2.5 million note payable and the terms of the new $15 million credit facility.
- Goodwill Accounting: Verify the impact of SFAS No. 142 on the cessation of goodwill amortization and the results of the impairment test.
- Product Mix: Review the decline in domestic OEM sales (-12%) and vacuum-assisted delivery systems (-15%) versus growth in international sales.
- Share Count: Monitor the impact of share repurchases ($995k) and option exercises on diluted share count and future EPS.
- Litigation Recovery: Track the status of damages recovery from the patent infringement lawsuit mentioned in management commentary.